AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 211 min read$TWST

Cho Dennis sold $1.8M of TWST

Cho Dennis (See Remarks) sold 14,205 shares of Twist Bioscience Corp (TWST) at $129.75 ($1.84M total) on 2026-08-19 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Cho Dennis
Published Aug 21, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 21, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TWST
Bearish
medium confidence
Mentioned
$TWST
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTBearishLow
01

Why it matters

The disclosed sale provides fresh data on insider holdings and may influence short‑term trading decisions.

02

Market read

Insider sales are closely watched by traders; this $1.8M sale is material for TWST.

03

What to watch

Potential upcoming financing needs or tax planning could be driving the sale.

Relevance 5/10Novelty 7/10Timing: today

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources of new information.

Company-level read

Ticker impact

$TWSTBearishMedium confidence
Context

Officer Cho Dennis sold 14,205 shares of Twist Bioscience for $1.84M via a 10b5‑1 plan.

Expected impact

Possible modest downside pressure over the next few days.

Evidence & confidence

The sale size ($1.8M) is material for a mid‑cap biotech and was executed through a pre‑arranged plan, suggesting a neutral to slightly bearish signal.

Market effects

Sector

May prompt scrutiny of insider activity across biotech peers.

Regional

Limited to US biotech sector.

Global

Low global impact.

Counterpoint

What could challenge this read

The sale was pre‑arranged under a 10b5‑1 plan and may not reflect current sentiment.

Key entities

  • Company
    Twist Bioscience Corp

    US‑listed biotech company (NASDAQ: TWST).

  • Officer
    Cho Dennis

    Company officer executing a 10b5‑1 sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TWST insider trading history →

Related articles

OCT 5
$TWSTHigh

Twist Bioscience TWST Stock Jumps On AI Drug Discovery Deals

Twist Bioscience (TWST) stock rose 10.19% after announcing AI drug discovery deals with Eli Lilly's TuneLab. The company reported $118.4M in quarterly revenue, a $35.1M net loss, and positive operating cash flow of $1.1M. Analysts have raised price targets, with Guggenheim setting it at $212. TWST is seen as a key player in AI-driven biotech.

timothysykes.com3 min
SEP 24
$TWSTMed

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Bullish Target Hike

Twist Bioscience (TWST) stock rose 16.21% after announcing a partnership with Eli Lilly's AI drug discovery platform, TuneLab. The company reported Q3 revenue of $118.4M, with a gross margin of 52% but a net loss of $35.1M. Leerink raised its price target to $160, citing the AI-driven opportunity. TWST is trading at a high valuation with a price-to-sales ratio over 25.

timothysykes.com3 min
SEP 24
$TWSTMed

Twist Bioscience Stock Jumps As AI Deals Fuel Bullish Target Hike

Twist Bioscience (TWST) stock rose 8.35% on September 24, 2026, driven by its AI partnership with Eli Lilly's TuneLab platform. The company's stock has seen significant gains recently, trading at $171.74 from $139 over a few weeks. TWST reported quarterly revenue of $118.38M, with a net loss of $35.05M. Leerink raised its price target to $160, citing AI drug discovery opportunities.

timothysykes.com3 min